Use of serotonin reuptake inhibitors in patients with psoriasis is associated with a decreased need for systemic psoriasis treatment: a population-based cohort study
Use of serotonin reuptake inhibitors in patients with psoriasis is associated with a decreased need for systemic psoriasis treatment: a population-based cohort study
复制标题
DOI：
10.1111/joim.12093
复制
发表时间：
2013-09-01
影响因子：
11.1
通讯作者：
Fored, C. M.
中科院分区：
文献类型：
--
作者：
Thorslund, K.;Svensson, T.;Fored, C. M.
客观的。旨在研究使用血清素再摄取抑制剂 (SSRI) 是否会影响银屑病。设计。一项基于人群的队列研究。设置。 1997 年至 2006 年间瑞典患有斑块状银屑病的一般成年人口。国家患者登记册中总共发现了 69 830 名斑块型银屑病患者。研究对象是否接触过 SSRIs 是通过瑞典处方药登记册确定的。 2006 年 7 月 1 日至 2008 年 4 月 1 日期间，暴露于 SSRI 的受试者（n = 1282）在瑞典药房的 6 个月内两次开出 SSRI 处方，洗脱期为 1 年或更长。未接触 SSRI 的参考受试者 (n = 1282) 在年龄、居住县、性别、银屑病严重程度和季节变化方面进行了匹配。主要结果指标。银屑病严重程度的变化是通过接触 SSRIs 后 6 个月在非系统性和系统性银屑病治疗之间切换来定义的。结果。在 SSRI 暴露组中，从非系统性银屑病治疗转为系统性银屑病治疗的风险显着降低（比值比 0.44，95% 置信区间 0.28-0.68）。结论。银屑病患者使用 SSRI 与系统性银屑病治疗需求减少相关。
Objective. To investigate whether psoriasis is affected by the use of serotonin reuptake inhibitors (SSRIs).Design. A population-based cohort study.Setting. The general adult population with plaque psoriasis in Sweden between 1997 and 2006.Subjects. A total of 69 830 patients with plaque psoriasis were identified in the National Patient Register. Whether study subjects were exposed to SSRIs was identified through the Swedish Prescribed Drug Register. The SSRI-exposed subjects (n = 1282) had a prescription for SSRIs dispensed twice during 6 months at a Swedish pharmacy between 1 July 2006 and 1 April 2008, with a wash-out period of 1 year or longer. The reference subjects (n = 1282), who were not exposed to SSRIs, were matched for age, county of residence, sex, psoriasis severity and seasonal variation.Main outcome measure. Change in psoriasis severity defined by switching between nonsystemic and systemic psoriasis treatments 6 months after exposure to SSRIs.Results. The risk of switching from nonsystemic to systemic psoriasis treatments was significantly decreased in the SSRI-exposed group (odds ratio 0.44, 95% confidence interval 0.28-0.68).Conclusion. SSRI use in patients with psoriasis is associated with a decreased need for systemic psoriasis treatment.